Sarah Meibusch leads business operations at QAAFI, a global leader in agriculture and food research and innovation.
She has responsibility for the >$35m p.a. financial operations and strategic development of QAAFI, and manages the 24 FTE business and operational staff.
A Graduate of the Australian Institute of Company Directors, Sarah has over 16 years of leadership experience in both the for-profit and not-for-profit life sciences sector in Australia and internationally. She holds a First Class Honours degree in Agricultural Science from the University of Queensland and a Masters degree from Cornell University.
As principal of her own consulting firm, Sarah provides representation for global biotech and pharmaceutical companies in the Asia Pacific region. Her consultancy work includes development of an international market strategy for a start-up gene expression diagnostics company, biotech mergers and stakeholder surveys.
Prior to her appointment at QAAFI, Sarah was previously the Chief Operating Officer, Commercialisation for the Beef Cooperative Research Centre for Genetic Technologies (Beef CRC) where she managed the business operations of the Beef CRC, including investment of research towards industry relevant outputs. Sarah implemented a wind up plan for the organisation after 20 years operation, involving resolution of complex issues regarding IP with stakeholders.
Sarah previously held the position of Vice President of Business Development at Progen Pharmaceuticals, an oncology drug development biotechnology company and was the Manager of Business Development at Pyxis Genomics, a Chicago-based animal biotechnology company. During her six years at Progen Pharmaceuticals she was part of the team that raised over $125 million via five capital raisings. She co-authored several multi-million dollar grant applications and identified and helped to execute the $22 million acquisition of a US private oncology drug development company.